This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Dendreon's Provenge Problems Reach Terminal Stage

A few more thoughts and questions:

1. Dendreon management blamed the weak $80 million Provenge quarter, in part, on a significant increase in the number of patients who cancelled appointments for their first infusions. Dendreon said the "schedule yield" issue became particularly problematic in late June as the quarter ended.

Late June? Hmmm… what could have happened earlier in June to persuade patients to ditch Provenge? Might it have been Johnson & Johnson (JNJ - Get Report) presenting strong Zytiga "pre-chemo" data at the big ASCO cancer conference just a few weeks earlier?

Dendreon insists that Zytiga is not having an impact on Provenge but common sense argues otherwise. It seems pretty clear that Provenge has a demand problem and it's not going to get any better with Zytiga on a path towards approval in the pre-chemo setting and Medivation's (MDVN - Get Report) MDV3100 moving fast behind it.

2. The deep cost-cutting announced by Dendreon Monday is the right strategic move but doesn't seem to be enough given Provenge's demand problems. Yes, Dendreon can now reach break-even at a $400 million annualized Provenge run rate (down from $500 million in annualized sales) but to get there, the company must grow sales by 25%. From where is that growth going to come? And when?

Johnson and his new team won't provide sales guidance for the rest of 2012 and admitted the company's "sales challenges" with Provenge wont resolve until early 2013. The Street has Dendreon doing $385 million in Provenge sales this year. Obviously, that consensus estimate is going to be chopped significantly by the time the stock opens for trading Tuesday.

3. Oncologists hate Provenge. They're not prescribing the drug to their prostate cancer patients so why does Dendreon insist on wasting money and resources trying to convince them otherwise? The company would be more effective if they focused solely on marketing Provenge to urologists.

4. Why are Dendreon sales reps leaving the company in droves? Are they applying for jobs with Johnson & Johnson and Medivation?

5. Dendreon is not going to be acquired. Not anytime soon, anyway, and certainly not for a premium price. Sure, Dendreon dead-enders will try to recycle the old rumors -- Celgene (CELG)! AstraZeneca (AZN)! Amgen (AMGN)! -- but it's just a futile exercise. One day, the Dendreon bulls may get their wish but only if a large pharmaceutical company is able to buy the company at what amounts to a biotech yard sale.

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to

>To submit a news tip, send an email to:

Follow TheStreet on Twitter and become a fan on Facebook.
Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.
2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
DNDN $0.06 -6.02%
JNJ $102.37 0.00%
MDVN $41.68 0.00%
AAPL $117.81 0.00%
FB $105.45 0.00%


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs